FDA Approves First-of-its-Kind Glaucoma Treatment
2023年12月15日 · The U.S. Food and Drug Administration has approved a new treatment for glaucoma, iDose® TR (travoprost intracameral implant, 75 mcg). iDose TR is a first-of-its kind treatment that is designed to provide up to three years of 24/7, continuous drug therapy directly inside the eye, helping people with glaucoma take control over the elevated eye ...
Santen Receives FDA Approval for Omlonti for Primary Open-Angle Glaucoma
The new glaucoma eye drop medication increases drainage through the eye's conventional outflow pathways via a unique pharmacological action. Santen and UBE announced that the FDA has approved Omlonti (omidenepag isopropyl ophthalmic solution) 0.002% eye drops for the reduction of elevated IOP in patients with primary open-angle glaucoma or ...
2024 Will See Major Advances in Glaucoma Care - Medscape
2024年2月8日 · Three new treatments for dry eye disease and a new procedure and remote monitoring platform for glaucoma are due to debut in 2024, with more in the pipeline.
Two New Glaucoma Medications: Learn More - BrightFocus
2021年7月15日 · These new medications hold great promise in lowering eye pressure by directly targeting the tissue that is diseased in glaucoma, the trabecular meshwork. Now we are eager to see how these new medications perform in a real-world setting in treating glaucoma patients.
An overview of new glaucoma medications - EyeWorld
EyeWorld spoke with Drs. Khouri, Lee, and Serle for a comprehensive overview of these three novel glaucoma medications. “These new agents are thought to target the trabecular meshwork, which is the site of pathology leading to ocular hypertension in glaucoma,” Dr. Khouri said.
Product Spotlight: The First Preservative-free Eye Drop for Glaucoma …
With the FDA’s approval of Thea’s Iyuzeh, there is now a preservative-free eye latanoprost drop to treat primary open-angle glaucoma or ocular hypertension in the United States. Iyuzeh (latanoprost ophthalmic solution) 0.005% is marketed as Monoprost outside of the United States.
What's New in the Glaucoma Drug and Surgical Device Pipeline …
2023年7月11日 · Researchers are continually working to develop new eye drops for glaucoma treatment, hoping to improve efficacy, reduce side effects, and provide better patient adherence. Many new glaucoma drops aim to strengthen current medications, while others work through entirely new mechanisms.
FDA Approves Omlonti Eye Drops for Glaucoma Patients
2022年9月26日 · Santen Inc. and UBE Corp. announced that the U.S. Food and Drug Administration has approved Omlonti eye drops for the reduction of elevated intraocular pressure in patients with primary open-angle glaucoma or ocular hypertension.
New Medical Therapies Offer Hope for Glaucoma Patients
2018年3月6日 · The first, Vyzulta™ (latanoprostene bunod ophthalmic solution), developed by Bausch + Lomb is a dual action, once per day eye drop. The second new eye drop, once-daily Rhopressa® (netarsudil ophthalmic solution) from Aerie Pharmaceuticals, Inc., is a novel mechanism of action designed to enhance fluid outflow and reduce the production of ...
List of Ophthalmic glaucoma agents - Drugs.com
Ophthalmic glaucoma agents are used to reduce eye pressure in glaucoma. Glaucoma refers to a group of eye conditions that lead to damage to the optic nerve,which in most cases, is due to increased pressure in the eye. More than one type of eye drop may be used at a time, and regular use is very important.
- 某些结果已被删除